Member Info for leewill39

No worries Wiggly its a very common assumption that Precision contains affimers:)

You have to hand it Avacta, they have a potential blockbuster platform on their hands with Affimer but that didn't stop hunting out another huge opportunity with Precision.

The tie up with Tufts was originally about the TMAC but they discovered that the chemistry rendered the Chemo inactive until cleaved by FAP.

I wonder if Tufts were aware of this prior to the Avacta tie up would they have granted an exclusive licence?

Its actually a real advantage that the Precision platform doesn't involve affimers as it spreads the risk. If in the very slim chance that the affimers don't work in humans, we can fall back on Precision and diagnostics.

Biotech is always a risky investment prospect but we have 3 shots on goal - Affimer therapeutics, Precision and Affimer diagnostics( already proven)

If both Affimer and Precision platforms are proved safe in humans(I think it will) we are on track to be one of most exciting biotech's on the planet imo.

And don't even get me started on TMAC:)

No need to worry about the affimer as there isn't one in AVA6000.

The Precision chemistry is a substrate licenced from Tufts University

3,4100,000 secondary school children

39 school weeks

Twice weekly = 265,980,000 tests per year.

Off the top my head:)

https://explore-education-statistics.service.gov.uk/find-statistics/school-pupils-and-their-characteristics

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:
“I am very pleased indeed that we have established this research partnership with OncoSec. Avacta is receiving a lot of interest in the Affimer platform for gene delivery and this is the third collaboration in this hugely important area following our partnerships with Moderna Therapeutics and FIT Biotech.

“Gene delivery is a very exciting new area and one in which I believe we can establish Affimer technology as the protein platform of choice because of the technical benefits of using a small, simple protein for this application. This is potentially a very large opportunity for Avacta and a successful outcome of the collaborative work with OncoSec would not only create the potential for the two companies to consider future co-developments but would also support Affimer licensing deals more widely in this rapidly growing field. We look forward to updating the market on our progress.”

Affimer biotherapeutics are a novel engineered alternative to antibodies based on a fully human small protein that can be quickly engineered to bind with high specificity and affinity to a wide range of protein targets. The size and biophysical characteristics of Affimer proteins make them an ideal candidate for gene delivery approaches.

Agreed, I do like the Avacta management team. Alistair Smith, Eliot Forster and Mike Owen are a hugely impressive trio imo, I also like what I’ve seen from Neil Bell so far also.

Gene delivery is another area which is looking increasing likely that the affimer technology will excel in, certainly Moderna, Daewoong and Oncosec seem to think so.

So many opportunities and “shots in goal” If they all come off then I suspect 3.9 billion wouldn’t even get Alistair Smith out of bed:)

Yep, Ablynx’s had multiple programs in the clinic and very big partners also.

However, Avacta does have the huge benefit of having a plant based version of therapeutic affimer which can be used for diagnostics.

It also has the precision platform which if proven in humans later this year is addressing a 100 billion dollar market.

The combination of the 2 platforms to create TMAC drug conjugates is the most exciting program imo. If the amazing animal data is replicated in humans, Avacta and Tufts have a blockbuster cancer therapy on their hands.

Alistair Smith is in record saying he thinks the Affimer platform is the best of the mimetic platforms. Certainly going to be a very interesting year for the Avacta Group:)

Actually Rich is right....

Rx: A medical prescription. The symbol "Rx" is usually said to stand for the Latin word "recipe" meaning "to take." It is customarily part of the superscription (heading) of a prescription.

I think RX is research use but might be wrong.

TX is usually used for therapeutics.

It’s not just the improved performance....

Affimer reagents are:
1. Quicker to produce
2. Cheaper to produce
3. Better consistency across batches
4. More stable
5. More temperature resistant
6. Better shelf life
7. Very easy to mass produce
8. Can quickly be tweaked for variants.

What’s not to like:)

No need to have it on the front page as the Government have secured all supply:)

https://www.linkedin.com/posts/petrossarantos_results-of-initial-evaluation-of-sars-cov-activity-6767370449094496256-UGJd/

"Excellent results from the first clinical study in Spain #AVCT"

Incredible result!!!

Well done to the amazing scientists at Avacta.

Never in doubt:)

Check out the new guy at Avacta.....diagnostics unit again!!

https://www.linkedin.com/in/petrossarantos/
Petros Sarantos
Head of Product Management, Diagnostics at Avacta

Experienced in an international business environment with a demonstrated history of working in the medical device industry. Strong entrepreneurship professional skilled in Medical Devices, Life Sciences, and Marketing Strategy.

- Strategic marketing professional with 10+ years of significant and progressive global experience in IVD (immunoassays, instrumentation, molecular diagnostics) and international life science business

- Proven competence and achievement in the development, launch and life-cycle management of products within global clinical application groups and portfolios

- Experienced communicator both internally amongst key stakeholders in the organisation, and externally towards customers and key partners; bilingual in English and Greek; good command of French and Italian

- Skilled strategist who can prepare strategic plans and develop workable portfolio plans adapted to market conditions and perceived drivers (customers - competition - regulations)

- Reliable point of reference for local sales units, customer feedback, and new product development stakeholders within the organisation

QD do you realise how ridiculous you look right now?

This is possibly the biggest load of tripe I have ever read on a here.......completely pointless!!!

Good to see you back Spike.

I think Alistair is being very careful with his comments. We know PA consulting are building capacity for 60m tests per month. I don’t think at this stage Big Al can mention that this can be used for Avacta if clinical data is as good as lab performance. Who knows there may even be a white label/NHS test which is the Avacta in all but name.

We also know Medusa19 are scaling to 50m per month and they now have ISO 13485 accreditation, where’s this going not on their antibody test i know:)

If Avacta get anywhere near their lab performance in the field then capacity will be made available to Avacta globally imo.

Which company has partnered, been in discussion or linked with:
1. Mologic
2. Global Access Diagnostics or GAD
3. BBI Solutions
4. Abingdon Health
5. Omega Diagnostics
6. Boris Johnson( round table discussion Aug 20)
7. Chris Molloy "#consortium #breakthe chain"

Which company has?
1. Been increasing its lab space protein production capacity
2. Recruiting scientists with LFD experience
3. Recruiting production scientists with large scale protein purification experience
4. Building a IVD team and headhunted a very experienced guy from Omega skilled in rapid test manufacturing
5. Moving key staff over to its diagnostics unit, operations director, marketing manager, quality manager
6. Developed an anterior nasal swab version which government is giving priority to

Which companies CEO has:
1. Detailed the exact mass testing plan that we know is about to be launched.
2. Communicated in a strange way since September almost as is if he subject to a strict NDA
3. Has described Covid as "once in a lifetime" driver of scale
4. Believes the company can compete with Thermofisher, Roche and Abbot
5. Shared they are working with Novarum - who we know have been awarded a government contract.

Answers on a postcard......

All roads lead to Wetherby:)

David Wilson is well connected at BIDVA.....

https://www.linkedin.com/in/davidswilson/?originalSubdomain=uk
Leading an international team developing and executing the commercial strategy for in vitro diagnostic applications of Affimer reagents, including licensing and product development.
Chair, Near Patient Testing Working Party, British In Vitro Diagnostics Association (BIVDA)

Keep joining them dots:)

We might be working with Bond also, look who commented on David Wilsons post this week...

https://www.linkedin.com/posts/davidswilson_commercial-partnership-with-mologic-avacta-activity-6764438454177669120-jyAN/

Philip D Groom
Commercial Director (Global) Bond Digital Health / Chair BIVDA Digital working party

"No that's a powerful partnership!! Congratulations"